Cited by

• Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients.

  Ding L, Zhang Z, Xu Y, Zhang Y. Ding L, et al. Bioengineered. 2017 Jul 4;8(4):383-392. doi: 10.1080/21655979.2016.1235101. Epub 2017 Jan 11. Bioengineered. 2017. PMID: 28075663 Free PMC article.
• Prognostic significance of Ki67 in Chinese women diagnosed with ER⁺/HER2^- breast cancers by the 2015 St. Gallen consensus classification.

  Hu Y, Gu R, Zhao J, Yang Y, Liu F, Jin L, Chen K, Jia H, Wang H, Liu Q, Su F, Jia W. Hu Y, et al. BMC Cancer. 2017 Jan 6;17(1):28. doi: 10.1186/s12885-016-3021-7. BMC Cancer. 2017. PMID: 28061893 Free PMC article.
• Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

  Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members. Coates AS, et al. Ann Oncol. 2015 Aug;26(8):1533-46. doi: 10.1093/annonc/mdv221. Epub 2015 May 4. Ann Oncol. 2015. PMID: 25939896 Free PMC article.
• Citron kinase (CIT-K) promotes aggressiveness and tumorigenesis of breast cancer cells in vitro and in vivo: preliminary study of the underlying mechanism.

  Meng D, Yu Q, Feng L, Luo M, Shao S, Huang S, Wang G, Jing X, Tong Z, Zhao X, Liu R. Meng D, et al. Clin Transl Oncol. 2019 Jul;21(7):910-923. doi: 10.1007/s12094-018-02003-9. Epub 2018 Dec 18. Clin Transl Oncol. 2019. PMID: 30565087
• Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study.

  Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marmé F, Jäger D, Kauczor HU, Stieber A, Lindel K, Debus J, Golatta M, Schütz F, Sohn C, Heil J, Schneeweiss A. Hennigs A, et al. BMC Cancer. 2016 Sep 15;16(1):734. doi: 10.1186/s12885-016-2766-3. BMC Cancer. 2016. PMID: 27634735 Free PMC article.